Rep. Byron Donalds Buys IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares

Representative Byron Donalds (R-Florida) recently bought shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX). In a filing disclosed on October 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in IDEXX Laboratories stock on September 4th. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 9/4/2025.
• Sold $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 9/4/2025.
• Sold $1,001 – $15,000 in shares of Fortinet (NASDAQ:FTNT) on 9/4/2025.
• Sold $1,001 – $15,000 in shares of Tradeweb Markets (NASDAQ:TW) on 9/4/2025.
• Sold $1,001 – $15,000 in shares of Molina Healthcare (NYSE:MOH) on 9/4/2025.
• Sold $1,001 – $15,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 9/4/2025.
• Sold $1,001 – $15,000 in shares of Trade Desk (NASDAQ:TTD) on 9/4/2025.
• Sold $1,001 – $15,000 in shares of Fiserv (NYSE:FI) on 9/4/2025.
• Sold $1,001 – $15,000 in shares of Howmet Aerospace (NYSE:HWM) on 8/7/2025.
• Sold $1,001 – $15,000 in shares of Deckers Outdoor (NYSE:DECK) on 8/7/2025.

IDEXX Laboratories Trading Down 0.2%

NASDAQ:IDXX opened at $628.75 on Friday. The company has a fifty day moving average of $639.88 and a 200 day moving average of $540.49. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $50.30 billion, a P/E ratio of 52.35, a P/E/G ratio of 4.08 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the business posted $2.44 EPS. The firm’s revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Institutional Trading of IDEXX Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of IDEXX Laboratories by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company’s stock worth $4,139,001,000 after buying an additional 146,427 shares during the period. Geode Capital Management LLC grew its position in shares of IDEXX Laboratories by 2.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock worth $1,317,875,000 after buying an additional 54,402 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of IDEXX Laboratories by 71.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock worth $835,244,000 after buying an additional 825,965 shares during the period. Bank of New York Mellon Corp grew its position in shares of IDEXX Laboratories by 156.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after buying an additional 884,808 shares during the period. Finally, Invesco Ltd. grew its position in shares of IDEXX Laboratories by 0.5% in the 1st quarter. Invesco Ltd. now owns 1,166,406 shares of the company’s stock worth $489,832,000 after buying an additional 5,418 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on IDXX shares. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday. Piper Sandler reissued a “neutral” rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. UBS Group assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, October 1st. They set a “neutral” rating and a $720.00 price objective on the stock. Finally, Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a research report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $656.50.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 1,200 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $656.53, for a total transaction of $787,836.00. Following the sale, the executive vice president directly owned 16,807 shares of the company’s stock, valued at approximately $11,034,299.71. This represents a 6.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael G. Erickson sold 406 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the sale, the executive vice president directly owned 11,287 shares in the company, valued at $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is owned by insiders.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.